Lifesci Capital Weighs in on TARS Q1 Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARSFree Report) – Equities research analysts at Lifesci Capital issued their Q1 2025 earnings estimates for Tarsus Pharmaceuticals in a research note issued to investors on Wednesday, February 26th. Lifesci Capital analyst C. Jubinville expects that the company will post earnings of ($0.78) per share for the quarter. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. Lifesci Capital also issued estimates for Tarsus Pharmaceuticals’ Q1 2025 earnings at ($0.78) EPS, Q2 2025 earnings at ($0.48) EPS and Q3 2025 earnings at ($0.31) EPS.

Tarsus Pharmaceuticals (NASDAQ:TARSGet Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The business had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million.

TARS has been the topic of several other reports. Oppenheimer upped their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. The Goldman Sachs Group upped their target price on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research report on Friday, November 15th. Barclays lowered their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday. Guggenheim restated a “buy” rating and set a $78.00 target price (up from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Finally, HC Wainwright reiterated a “buy” rating and issued a $73.00 price target on shares of Tarsus Pharmaceuticals in a research report on Wednesday. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $61.33.

Read Our Latest Analysis on TARS

Tarsus Pharmaceuticals Trading Up 2.1 %

Shares of TARS opened at $44.48 on Friday. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The firm’s 50-day moving average is $50.97 and its two-hundred day moving average is $43.25. Tarsus Pharmaceuticals has a twelve month low of $20.08 and a twelve month high of $57.28. The firm has a market capitalization of $1.71 billion, a P/E ratio of -11.67 and a beta of 1.01.

Institutional Trading of Tarsus Pharmaceuticals

Several large investors have recently modified their holdings of TARS. Toronto Dominion Bank acquired a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter valued at approximately $105,714,000. Jennison Associates LLC lifted its stake in shares of Tarsus Pharmaceuticals by 47.2% during the third quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock valued at $71,653,000 after buying an additional 698,712 shares during the period. Lord Abbett & CO. LLC lifted its stake in shares of Tarsus Pharmaceuticals by 115.2% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company’s stock valued at $70,873,000 after buying an additional 685,111 shares during the period. Millennium Management LLC lifted its stake in shares of Tarsus Pharmaceuticals by 189.4% during the fourth quarter. Millennium Management LLC now owns 644,010 shares of the company’s stock valued at $35,659,000 after buying an additional 421,495 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in shares of Tarsus Pharmaceuticals by 2,088.8% during the third quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock valued at $14,477,000 after buying an additional 420,057 shares during the period. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Company Profile

(Get Free Report)

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

Read More

Earnings History and Estimates for Tarsus Pharmaceuticals (NASDAQ:TARS)

Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.